Article
Oncology
Evelien J. M. de Jong, Quisette P. Janssen, Tessa F. A. Simons, Marc G. Besselink, Bert A. Bonsing, Stefan A. W. Bouwense, Sandra M. E. Geurts, Marjolein Y. Homs, Vincent E. de Meijer, Vivianne C. G. Tjan-Heijnen, Hanneke W. M. van Laarhoven, Liselot B. J. Valkenburg-van Iersel, Johanna W. Wilmink, Lydia G. van der Geest, Bas Groot Koerkamp, Judith de Vos-Geelen
Summary: In a nationwide cohort of patients with pancreatic ductal adenocarcinoma, adjuvant GEMCAP was associated with superior survival compared to GEM monotherapy.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Oncology
Sora Kang, Changhoon Yoo, So Heun Lee, Dongwook Oh, Tae Jun Song, Sang Soo Lee, Jae Ho Jeong, Do Hyun Park, Dong Wan Seo, Jin-hong Park, Dae Wook Hwang, Ki Byung Song, Jae Hoon Lee, Woohyung Lee, Bong Jun Kwak, Sarang Hong, Heung-Moon Chang, Baek-Yeol Ryoo, Kyu-pyo Kim, Song Cheol Kim
Summary: This retrospective study evaluated the efficacy and safety of GemCap versus Gem as adjuvant chemotherapy in an Asian population. The results showed that GemCap had better overall survival and consistent clinical outcomes compared to Gem. Further evaluation of optimal adjuvant chemotherapy is necessary due to the emergence of mFOLFIRINOX as the new standard treatment for resected PDAC patients.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2022)
Article
Oncology
Margaret A. Tempero, Uwe Pelzer, Eileen M. O'Reilly, Jordan Winter, Do-Youn Oh, Chung-Pin Li, Giampaolo Tortora, Heung-Moon Chang, Charles D. Lopez, Tanios Bekaii-Saab, Andrew H. Ko, Armando Santoro, Joon Oh Park, Marcus S. Noel, Giovanni Luca Frassineti, Yan-Shen Shan, Andrew Dean, Hanno Riess, Eric Van Cutsem, Jordan Berlin, Philip Philip, Malcolm Moore, David Goldstein, Josep Tabernero, Mingyu Li, Stefano Ferrara, Yvan Le Bruchec, George Zhang, Brian Lu, Andrew V. Biankin, Michele Reni
Summary: In this randomized, open-label trial, adjuvant nab-paclitaxel + gemcitabine was compared with gemcitabine alone for resected pancreatic ductal adenocarcinoma. The study found that although nab-paclitaxel + gemcitabine showed favorable overall survival, it did not meet the primary endpoint of independently assessed disease-free survival.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Tao Ma, Xueli Bai, Qichun Wei, Yongjie Shui, Mengyi Lao, Wen Chen, Bingfeng Huang, Risheng Que, Shunliang Gao, Yun Zhang, Wei Chen, Ji Wang, Tingbo Liang
Summary: This study suggests that adjuvant stereotactic body radiation therapy (SBRT) does not provide a survival benefit or improve local disease control in resected stage II pancreatic adenocarcinoma (PDAC).
Article
Pharmacology & Pharmacy
Susann Theile, Julia Sidenius Johansen, Dorte Lisbet Nielsen, Benny Vittrup Jensen, Carsten Palnaes Hansen, Jane Preuss Hasselby, Sverrir Vidalin Eiriksson, Inna Markovna Chen
Summary: This phase 2 trial evaluated the efficacy and safety of chitooligosaccharides in addition to adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma. Despite premature termination of the trial, the results suggest that chitooligosaccharides may be safe for use in this patient population.
Article
Gastroenterology & Hepatology
Hyehyun Jeong, Kyu-pyo Kim, Jae Ho Jeong, Dae Wook Hwang, Jae Hoon Lee, Ki-Hun Kim, Deok-Bog Moon, Myung Ah Lee, Se Jun Park, Hong Jae Chon, Jin-hong Park, Ji Sung Lee, Baek-Yeol Ryoo, Changhoon Yoo
Summary: The effectiveness of adjuvant gemcitabine plus cisplatin (GemCis) therapy was evaluated in a homogeneous group of high-risk patients with resected, lymph node-positive extrahepatic cholangiocarcinoma. The study found that adjuvant GemCis did not improve survival outcomes compared with capecitabine in this patient population.
Article
Oncology
Rolf D. Issels, Stefan Boeck, Uwe Pelzer, Ulrich Mansmann, Pirus Ghadjar, Lars H. Lindner, Markus Albertsmeier, Martin K. Angele, Michael Schmidt, Yujun Xu, Marcus Bahra, Johann Pratschke, Michael Schoenberg, Wolfgang E. Thasler, Christoph Salat, Oliver J. Stoetzer, Wolfram T. Knoefel, Dirk Graf, Rudiger Wessalowski, Verena Keitel-Anselmino, Alfred Koenigsrainer, Michael Bitzer, Daniel Zips, Michael Bamberg, Rainer Fietkau, Oliver Ott, Maciej Kawecki, Lucian Wyrwicz, Piotr Rutkowski, Markus Rentsch, Juliana Ababei, Peter Reichardt, Marco Rigamonti, Bernhard Weber, Sultan Abdel-Rahman, Katharina Tschoep-Lechner, Karl-Walter Jauch, Christiane J. Bruns, Helmut Oettle, Michael von Bergwelt-Baildon, Volker Heinemann, Jens Werner
Summary: In this randomized controlled trial, the addition of cisplatin to gemcitabine with regional hyperthermia did not significantly improve disease-free survival in resected pancreatic ductal adenocarcinoma, but it showed a difference in post-recurrence survival and a trend for improved overall survival.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Kevin M. Turner, Aaron M. Delman, Allison M. Ammann, Davendra Sohal, Olugbenga Olowokure, Kyuran A. Choe, Milton T. Smith, Jordan R. Kharofa, Syed A. Ahmad, Gregory C. Wilson, Sameer H. Patel
Summary: The study found that adjuvant chemotherapy is associated with improved overall survival in resected Stage IA PDAC patients, especially in those with good prognostic features. However, in certain specific cohorts, such as those with body/tail tumors or all good prognostic features, adjuvant chemotherapy did not lead to improved survival. Further research is needed to personalize treatment for patients with PDAC.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Oncology
Hui Tang, Caixia Qiao, Jun Lu, Yuejuan Cheng, Menghua Dai, Taiping Zhang, Junchao Guo, Yingyi Wang, Chunmei Bai
Summary: This study compared the efficacy and safety of adjuvant gemcitabine plus S-1 (GS) with S-1 monotherapy for pancreatic ductal adenocarcinoma (PDAC). The results showed that adjuvant S-1 monotherapy was noninferior to the GS regimen in disease-free survival and overall survival, with better tolerability.
Article
Oncology
Jung Hyun Jo, Yong-Tae Kim, Ho Soon Choi, Ho Gak Kim, Hong Sik Lee, Young Woo Choi, Dong Uk Kim, Kwang Hyuck Lee, Eui Joo Kim, Joung-Ho Han, Seung Ok Lee, Chang-Hwan Park, Eun Kwang Choi, Jae Woo Kim, Jae Yong Cho, Woo Jin Lee, Hyungsik Roger Moon, Mi-Suk Park, Sangjae Kim, Si Young Song
Summary: The combination of GV1001 with gemcitabine/capecitabine improves overall survival and time to progression in eotaxin-high patients with advanced PDAC.
BRITISH JOURNAL OF CANCER
(2023)
Article
Medicine, General & Internal
Enriqueta Felip, Nasser Altorki, Caicun Zhou, Tibor Csoszi, Ihor Vynnychenko, Oleksandr Goloborodko, Alexander Luft, Andrey Akopov, Alex Martinez-Marti, Hirotsugu Kenmotsu, Yuh-Min Chen, Antonio Chella, Shunichi Sugawara, David Voong, Fan Wu, Jing Yi, Yu Deng, Mark McCleland, Elizabeth Bennett, Barbara Gitlitz, Heather Wakelee
Summary: IMpower010 study demonstrated a disease-free survival benefit with adjuvant atezolizumab versus best supportive care in patients who underwent complete resection followed by adjuvant chemotherapy, especially in the subgroup whose tumors expressed PD-L1 on 1% or more of tumor cells.
Article
Gastroenterology & Hepatology
Dong Woo Shin, Jong-chan Lee, Jaihwan Kim, Yoo-Seok Yoon, Ho-Seong Han, Haeryoung Kim, Jin-Hyeok Hwang
Summary: Tailored adjuvant chemotherapy based on hENT1 staining shows excellent clinical outcomes in patients with resected PDA, including longer recurrence free survival and overall survival.
Article
Oncology
Victor Mortier, Felix Wei, Anna Pellat, Ugo Marchese, Anthony Dohan, Catherine Brezault, Maxime Barat, David Fuks, Philippe Soyer, Romain Coriat
Summary: Pancreatic cancer is projected to be the second deadliest cancer by 2030. A third of patients with pancreatic cancer undergo surgery followed by intravenous chemotherapy. This study investigated the impact of sarcopenia, measured through computer tomography, on the overall survival of patients with localized pancreatic ductal adenocarcinoma who received adjuvant chemotherapy. The results showed that sarcopenic patients had lower overall survival regardless of the type of chemotherapy used.
Article
Medicine, General & Internal
Yu-Pei Chen, Xu Liu, Qin Zhou, Kun-Yu Yang, Feng Jin, Xiao-Dong Zhu, Mei Shi, Guo-Qing Hu, Wei-Han Hu, Yan Sun, Hong-Fen Wu, Hui Wu, Qin Lin, Hui Wang, Ye Tian, Ning Zhang, Xi-Cheng Wang, Liang-Fang Shen, Zheng-Zheng Liu, Jing Huang, Xiu-Ling Luo, Ling Li, Jian Zang, Qi Mei, Bao-Min Zheng, Dan Yue, Jing Xu, San-Gang Wu, Yan-Xia Shi, Yan-Ping Mao, Lei Chen, Wen-Fei Li, Guan-Qun Zhou, Rui Sun, Rui Guo, Yuan Zhang, Cheng Xu, Jia-Wei Lv, Ying Guo, Hui-Xia Feng, Ling-Long Tang, Fang-Yun Xie, Ying Sun, Jun Ma
Summary: This study found that adding oral metronomic capecitabine as adjuvant chemotherapy significantly improved failure-free survival in patients with high-risk locoregionally advanced nasopharyngeal carcinoma, with a good safety profile. These results support the potential role of metronomic chemotherapy as an adjuvant therapy in the treatment of nasopharyngeal carcinoma.
Article
Oncology
Annika Kurreck, Johanna Weckwerth, Dominik P. Modest, Jana K. Striefler, Marcus Bahra, Sven Bischoff, Uwe Pelzer, Helmut Oettle, Stephan Kruger, Hanno Riess, Marianne Sinn
Summary: Isolated pulmonary metastasis, low tumor grading, low postoperative CA 19-9 levels, completeness of adjuvant gemcitabine-based treatment, number of relapse sites, and type of palliative first-line treatment are significant factors affecting overall survival and disease-free survival in patients with recurrent pancreatic ductal adenocarcinoma. The site of relapse and other prognostic factors may help stratify patients for future clinical trials and could impact subsequent survival. Further research is needed to identify differences in tumor biology and relapse patterns, reflecting the varying survival outcomes in PDAC patients.
EUROPEAN JOURNAL OF CANCER
(2021)
